The fragile X syndrome (FXS) is an X-linked condition and the leading monogenic cause of intellectual disability and autism (Bagni et al., 2012) ; it was first described by Martin and Bell in 1943. Patients with FXS show several neurological symptoms, including intellectual disability, hyperactivity, obsessive-compulsive disorders, anxiety, and autistic-like behavior (Jacquemont et al., 2007) . The causative gene FMR1 was identified in 1991 as a joint and concomitant effort by the laboratories of Stephen T. Warren, Ben A. Oostra, Jean-Louis Mandel, Grant R. Sutherland, and David L. Nelson. FMRP, the protein encoded by the FMR1 gene, is either absent or mutated in FXS patients (Bagni et al., 2012; Jacquemont et al., 2007) . FMRP binds to mRNA and regulates translation (Bagni et al., 2012) as well as transport and stability of its targets (Bassell and Warren, 2008; De Rubeis and Bagni, 2010) . Presumably, dysregulation of the mRNA targets causes the FXS phenotypes, and it is therefore important to understand which mRNAs are controlled by FMRP.
Several high-throughput approaches such as coimmunoprecipitation followed by microarray analysis (Brown et al., 2001 ), CLIP-RNA sequencing (Darnell et al., 2011 , Ascano et al., 2012 , and antibody-positioned-RNA amplification (APRA) (Miyashiro et al., 2003) led to the identification of hundreds of FMRP putative target mRNAs (>1,000 in brain and >6,000 in nonneuronal cells). Overall, FMRP was shown to bind almost 4% of the mouse brain transcriptome (Brown et al., 2001; Miyashiro et al., 2003; Darnell et al., 2011) . The effect of FMRP binding to the majority of these target mRNAs still needs to be elucidated. Here, we report on 40 bona fide FMRP targets for which mRNA binding and protein regulation have been reported in mammals by more than one study. The list is sorted by the number of studies reporting on the FMRP/mRNA functional interaction, ranked from orange (most frequent) to white (less frequent). Due to space constraints we needed to limit the list of targets; we apologize to our colleagues whose studies could not be included.
For each gene, the disease associated with the encoded protein is shown; diseases were compiled from the following databases: SFARIgene (https://gene.sfari.org), AutDB (http://autism.mindspec.org), SzGene (http://www.szgene.org), AlzGene (http://www.alzgene.org), PDGene (http://www.pdgene.org), Cosmic (http://cancer.sanger.ac.uk), Ingenuity Pathway Analysis (http://www.ingenuity.com), and GWAS studies.
As expected, many of the FMRP target mRNAs are linked to neurological disorders that can be correlated to aspects of the FXS phenotype, such as autism, schizophrenia, or major depressive disorder. The genes encode for proteins mostly involved in synaptic activity, cell adhesion, and cytoskeleton structure and remodeling, suggesting that dysregulation of these processes is responsible for the neurological phenotypes of FXS.
More than 20 years after its discovery, FMRP continues to reveal new and unexpected clinical presentations and molecular mechanisms. Some FMRP targets are linked to nonneurological disorders, raising the possibility that the FMRP also plays a role in other diseases. Indeed, FMRP is expressed in all tissues, although at lower levels than the brain. An involvement of FMRP in cancer has been shown: the protein is overexpressed in breast cancer (Lucá et al., 2013) , and patients with FXS show a decrease in cancer incidence (Lucá et al., 2013; Schultz-Pedersen et al., 2001 ).
Importantly, not one single gene regulated by FMRP can explain any given disease phenotype. Instead, the pathology appears to arise from the concerted dysregulation of a set of mRNAs, consituting the FMRP regulon, which, under physiologic conditions and at different developmental stages, is orchestrated by FMRP and its various protein interactors.
